There are 2934 resources available
3250 - Personalized treatment according to geriatric assessment in 1st line recurrent and/or metastatic (R/M) Head and Neck Squamous Cell Cancer (HNSCC) patients aged 70 or over. ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials
Presenter: Joel Guigay
Session: Proffered Paper – Head and neck cancer
Resources:
Abstract
Slides
Webcast
2064 - Cisplatin reduces costs and provides more quality adjusted life years (QALYs) than cetuximab in chemoradiotherapy for patients with HPV-Positive Oropharyngeal Cancer (HPV+OPC)
Presenter: David Jones
Session: Proffered Paper – Head and neck cancer
Resources:
Abstract
Slides
Webcast
3257 - A phase II study of Monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).
Presenter: Rachel Galot
Session: Proffered Paper – Head and neck cancer
Resources:
Abstract
Slides
Webcast
5378 - 2nd/3rd-line Nivolumab vs Nivo plus Ipilimumab in Malignant Pleural Mesothelioma: long-term results of IFCT-1501 MAPS2 phase 2R trial with a focus on hyperprogression (HPD)
Presenter: Gerard Zalcman
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Abstract
Slides
Webcast
1316 - SAKK 17/16: Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm Phase II trial.
Presenter: Yannis Metaxas
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Abstract
Slides
Webcast
803 - Durable anti-tumor activity of the multi-targeted inhibitor lenvatinib in patients with advanced or metastatic thymic carcinoma; Preliminary results from a multicenter phase II (REMORA) trial.
Presenter: Shoichi Itoh
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Abstract
Slides
Webcast
4445 - Association of tumor mutational burden with outcomes in patients with select advanced solid tumors treated with pembrolizumab in KEYNOTE-158
Presenter: Aurélien Marabelle
Session: Proffered Paper – Immunotherapy of cancer
Resources:
Abstract
Slides
Webcast
2365 - Durvalumab Activity in Previously Treated Patients Who Stopped Durvalumab without Disease Progression
Presenter: Siddharth Sheth
Session: Proffered Paper – Immunotherapy of cancer
Resources:
Abstract
Slides
Webcast
4019 - Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
Presenter: Susan Domchek
Session: Proffered Paper – Immunotherapy of cancer
Resources:
Abstract
Slides
Webcast
Drug-food interactions
Presenter: Marzia Del Re
Session: Individualised dosing of commonly used anti-cancer agents
Resources:
Slides
Webcast